Although in this study, prophylactic treatment with sunscreen failed to reduce the overall incidence of skin rash, the fact that the incidence of higher-grade skin rash was markedly reduced in the sunscreen arm of the study led the study investigators to conclude that the prophylactic use of sunscreen should be continued in patients receiving EGFR-targeted therapy. This evidence concerns the gene EGFR and exanthem.